The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Nice ramp InvestingWizard. Did you only just work out that stuff in your top post?! ;-)
I am in on this and confident of success. Whether I can bear the wait for the RNS is another question........
Here are the resolutions:
https://1v6gj215h9gy3y4dgh3it40h-wpengine.netdna-ssl.com/wp-content/uploads/2019/04/Notice-of-Annual-General-Meeting.pdf
Resolution 2: Approving the Directors’ Remuneration ReportAn ordinary resolution to approve the Directors’ Remuneration Report. The Directors’ Remuneration Report, which may be found on pages 20 to 34 of the 2018 Annual Report, gives details of the directors’ remuneration for the year ended 31 December 2018.The Company’s auditors, PricewaterhouseCoopers LLP, have audited those parts of the Directors’ Remuneration Report that are required to be audited and their report may be found on pages 35 to 39 of the 2018 Annual Report.The board considers that appropriate executive remuneration plays a vital part in helping to achieve the Company’s overall objectives and, accordingly, in compliance with legislation, shareholders will be invited to approve the Directors’ Remuneration Report. This resolution is subject to an ‘advisory vote’ by shareholders.
Then pages 20-34 of this:
https://1v6gj215h9gy3y4dgh3it40h-wpengine.netdna-ssl.com/wp-content/uploads/2019/04/2018-Annual-Report-Accounts-1.pdf
-Type A meeting held with the U.S. FDA on 3rd May to discuss the path forward
-Additional data likely will be required to address the Agency’s concern about a risk of liver toxicity, the size and scope of which will determine the specific next steps
-Motif Bio to provide an update once the minutes of the meeting are received
-Intention remains to partner Iclaprim upon marketing approval for commercialisation in the U.S. and other global markets
-Strengthen IP portfolio and partnering position in ex-U.S. markets by filing method-of-use patents covering fixed dose of Iclaprim
No idea what the resolutions were since they are not listed on the website at
http://ir.motifbio.com/news-releases/news-release-details/motif-bio-plc-notice-annual-general-meeting
where I expected. :-Z
There's no point deramping any more once you have bought the shares at as low a price as possible just before a predicted big rise. It would be a waste of his boss's money (and in fact, counterproductive now that his boss owns the shares) and SP250 is only going to post for what he's paid.
Do you still think he is a genuine troll and not a professional deramper? ROFL!!!
Nice chart, but IMO the increase will be even more pronounced given the drop from pre-CRL to post.
WTF are you smoking man??? If this gets the thumbs up from the FDA with patient monitoring caveats or labelling changes, this will go completely mental.
I have you on my potential blatent deramper list.
Amers, filtered you you utter cretin. Now have the dignity not to change your username!
Great RNS Amers at 3pm just as you told, thanks for the heads up!!!!
Nice pump Mr. 19 Posts.
This 20% rise is noise. Come on CRL minutes, where are you!?!?
At this point, if I buy shares in BMN am I just buying the price of Vanadium itself? That is what seems to be going on here. No effect of the future value of the company in the share price at all. Just the price of Vanadium.
Would be good to see their batteries get off the ground then the share price can include that in it.
Yes, good insight PrivateRyan. I think you're probably right.
mysteryguy, it is a fair point that the cystic fibrosis exploration may be a way to lessen a possible failed CRL attempt. I worry about that too, however have another look at the timing: they released the RNS about the tie up with Lamellar 2 days BEFORE the FDA meeting. (You meant Lamellar not Llanebar right?)
Remember that they went guns blazing into the meeting and have no 100% idea of the meeting outcome until they receive the minutes so on balance, I think that there are no firm conclusions to be drawn about the tie up.
The fact that the AI known as SP250 keeps posting gives me massive faith in this share. Someone so keen to use an AI to deramp a share must have some serious belief that the share will rocket (i.e. they want to deramp to buy low). The deramping is going to get really hard until just before the minutes are released before the AGM so I watch this AI with amusement!
I think I would be much more concerned if it was someone so blatently ramping the share as that suggests they want to get off at as high a point as possible before their believed share crash.
Apologies if these theories are obvious to veterans!
PrivateRyan, I'm not sure exactly what you mean regarding marketeers. Did you mean before the attempt in February to get approval?
Thanks. Missed that.
How did you find out about the AGM? I didn't receive an email from MTFB about this and neither is there any info on their investor section of the website. Thanks.